Cargando…
P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430448/ http://dx.doi.org/10.1097/01.HS9.0000846184.35066.7a |
| _version_ | 1784779771473821696 |
|---|---|
| author | McDonald, A. Malherbe, J. L. R. Kulasekararaj, A. Füreder, W. Griffin, M. Cornpropst, M. Farmer, M. K. Kargl, D. Collins, D. Sheridan, W. Risitano, A. |
| author_facet | McDonald, A. Malherbe, J. L. R. Kulasekararaj, A. Füreder, W. Griffin, M. Cornpropst, M. Farmer, M. K. Kargl, D. Collins, D. Sheridan, W. Risitano, A. |
| author_sort | McDonald, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430448 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94304482022-08-31 P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS McDonald, A. Malherbe, J. L. R. Kulasekararaj, A. Füreder, W. Griffin, M. Cornpropst, M. Farmer, M. K. Kargl, D. Collins, D. Sheridan, W. Risitano, A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430448/ http://dx.doi.org/10.1097/01.HS9.0000846184.35066.7a Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters McDonald, A. Malherbe, J. L. R. Kulasekararaj, A. Füreder, W. Griffin, M. Cornpropst, M. Farmer, M. K. Kargl, D. Collins, D. Sheridan, W. Risitano, A. P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS |
| title | P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS |
| title_full | P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS |
| title_fullStr | P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS |
| title_full_unstemmed | P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS |
| title_short | P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS |
| title_sort | p825: factor d inhibition with oral bcx9930 monotherapy leads to sustained control of hemolysis and symptoms over 48 weeks in subjects with paroxysmal nocturnal hemoglobinuria naïve to c5 inhibitors |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430448/ http://dx.doi.org/10.1097/01.HS9.0000846184.35066.7a |
| work_keys_str_mv | AT mcdonalda p825factordinhibitionwithoralbcx9930monotherapyleadstosustainedcontrolofhemolysisandsymptomsover48weeksinsubjectswithparoxysmalnocturnalhemoglobinurianaivetoc5inhibitors AT malherbejlr p825factordinhibitionwithoralbcx9930monotherapyleadstosustainedcontrolofhemolysisandsymptomsover48weeksinsubjectswithparoxysmalnocturnalhemoglobinurianaivetoc5inhibitors AT kulasekararaja p825factordinhibitionwithoralbcx9930monotherapyleadstosustainedcontrolofhemolysisandsymptomsover48weeksinsubjectswithparoxysmalnocturnalhemoglobinurianaivetoc5inhibitors AT furederw p825factordinhibitionwithoralbcx9930monotherapyleadstosustainedcontrolofhemolysisandsymptomsover48weeksinsubjectswithparoxysmalnocturnalhemoglobinurianaivetoc5inhibitors AT griffinm p825factordinhibitionwithoralbcx9930monotherapyleadstosustainedcontrolofhemolysisandsymptomsover48weeksinsubjectswithparoxysmalnocturnalhemoglobinurianaivetoc5inhibitors AT cornpropstm p825factordinhibitionwithoralbcx9930monotherapyleadstosustainedcontrolofhemolysisandsymptomsover48weeksinsubjectswithparoxysmalnocturnalhemoglobinurianaivetoc5inhibitors AT farmermk p825factordinhibitionwithoralbcx9930monotherapyleadstosustainedcontrolofhemolysisandsymptomsover48weeksinsubjectswithparoxysmalnocturnalhemoglobinurianaivetoc5inhibitors AT kargld p825factordinhibitionwithoralbcx9930monotherapyleadstosustainedcontrolofhemolysisandsymptomsover48weeksinsubjectswithparoxysmalnocturnalhemoglobinurianaivetoc5inhibitors AT collinsd p825factordinhibitionwithoralbcx9930monotherapyleadstosustainedcontrolofhemolysisandsymptomsover48weeksinsubjectswithparoxysmalnocturnalhemoglobinurianaivetoc5inhibitors AT sheridanw p825factordinhibitionwithoralbcx9930monotherapyleadstosustainedcontrolofhemolysisandsymptomsover48weeksinsubjectswithparoxysmalnocturnalhemoglobinurianaivetoc5inhibitors AT risitanoa p825factordinhibitionwithoralbcx9930monotherapyleadstosustainedcontrolofhemolysisandsymptomsover48weeksinsubjectswithparoxysmalnocturnalhemoglobinurianaivetoc5inhibitors |